EGFR and glioblastoma: Overall, this study highlighted how this experimental small molecule targets molecular vulnerability linked to energy metabolism in GBM cells by inhibiting the Y845 phosphorylation of EGFR and the following translocation on mitochondria, unlike other EGFR signaling inhibitors that increase mitochondrial translocation after treatments, such as staurosporine (ST) and Iressa (I), limiting their clinical efficacy [14].